Latest news with #JohnYu
Business Wire
3 days ago
- Business
- Business Wire
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,' the study authors presented their findings that demonstrated KROS 101's capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action. The study authors also indicated their study showed KROS 101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, enhancing the immune response by boosting cytokine production and tumor cancer cell killing. In addition, the study found that KROS101 reduced T reg-mediated suppression by reducing T reg populations, which reverses immune system suppression and enhances effector T cell activity. Further, the study showed KROS to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity and preventing T cell exhaustion. TRX518 was previously in clinical trials. The presentation can be accessed here. John Yu, M.D., Kairos CEO commented, 'These results strongly support continued study of KROS101 as a cancer immunotherapy, as they show strong activity in boosting the immune system while targeting and killing tumor cells. Its dual mechanism of action provides significant opportunity to a market that remains in desperate need of new solutions. We continue to believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing these findings with the medical and scientific communities while providing additional progress updates as appropriate.' About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential' or 'hopes' or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma's Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.
Associated Press
3 days ago
- Business
- Associated Press
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Jun 3, 2025-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,' the study authors presented their findings that demonstrated KROS 101's capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action. The study authors also indicated their study showed KROS 101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, enhancing the immune response by boosting cytokine production and tumor cancer cell killing. In addition, the study found that KROS101 reduced T reg-mediated suppression by reducing T reg populations, which reverses immune system suppression and enhances effector T cell activity. Further, the study showed KROS to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity and preventing T cell exhaustion. TRX518 was previously in clinical trials. The presentation can be accessed here. John Yu, M.D., Kairos CEO commented, 'These results strongly support continued study of KROS101 as a cancer immunotherapy, as they show strong activity in boosting the immune system while targeting and killing tumor cells. Its dual mechanism of action provides significant opportunity to a market that remains in desperate need of new solutions. We continue to believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing these findings with the medical and scientific communities while providing additional progress updates as appropriate.' About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential' or 'hopes' or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma's Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws. View source version on CONTACT: CORE IR Louie Toma [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: RESEARCH BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: Kairos Pharma, Ltd Copyright Business Wire 2025. PUB: 06/03/2025 08:15 AM/DISC: 06/03/2025 08:13 AM
Associated Press
17-02-2025
- Business
- Associated Press
CTCI Ranks Top 1% for Three Consecutive Years in S&P Global's Sustainability Yearbook
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- CTCI Group announced today that two group companies, CTCI Corporation and ECOVE Environment Corporation, have been selected for inclusion in S&P Global's Sustainability Yearbook 2025. CTCI Corp. was named as the top 1% corporate sustainability performer in the construction and engineering category, with the best Corporate Sustainability Assessment (CSA) score, for three years in a row. ECOVE Environment Corp., meanwhile, has been included as the yearbook member and named as the industry mover in the commercial services and supplies category for its strongest improvement. Both companies' stellar achievements underscore CTCI Group 's unwavering commitment to sustainability and its own vision to become a 'Guardian of Sustainable Earth.' S&P Global's Sustainability Yearbook is one of the world's most renowned assessments of corporate ESG (environmental, social, and governance) performance. Yearbook members and distinction levels are selected based on the companies' 2024 CSA scores. This year, over 7,690 companies across 62 industries assessed for the 2024 CSA were considered for inclusion in the Sustainability Yearbook. CTCI Corp. and ECOVE Environment Corp. were among the 780 companies that made it into the Sustainability Yearbook. CSA is the same basis on which the Dow Jones Sustainability Indices (DJSI) family select their lists of constituents. CTCI Corp. is proud to be selected for inclusion for ten consecutive years in the Dow Jones Sustainability Emerging Markets Index as announced last December. 'No factory, facility, or building in this world could become what they are without having been designed and constructed by engineering firms,' remarked CTCI Group Chairman John Yu. 'Across continents, the people at CTCI have a common vision to safeguard the Earth's sustainability, and with that vision they take a sustainability-oriented approach to implementing each project. Assuming responsibilities as a corporate citizen, CTCI joins hands with its global partners to make an impact in engineering. By closely aligning corporate operations and its own growth to its sustainability targets, CTCI has not only performed outstandingly in environmental, social, and governance aspects, but also in financial terms. It's a win-win for corporate profits and environmental protection.' Corporate governance-wise, CTCI Group recorded in 2024 an unprecedented NT$119.7 billion in consolidated revenue, NT$125.6 billion in new contracts—exceeding the NT$100 billion mark for the fifth consecutive year—and NT$333.4 billion in backlog, continuing to be at a high level. Among them, the low-carbon/environmental protection business accounted for as high as 60%. Carbon capture and storage (CCS), which is attracting investments globally, is one example. CTCI has secured the surface facilities EPC contract for the first carbon storage site in Taiwan and an EPC contract for a world-leading chip manufacturer's pilot carbon capture plant. This not only makes CTCI the first engineering firm in Taiwan with experience and track record in both upstream and downstream CCS projects, but also allows CTCI to make substantial contribution to reaching net zero emissions. Environment-wise, by advocating 'Green Engineering', CTCI ensures that the entire project lifecycle, from engineering, construction, to operation, can effectively save energy and reduce carbon emissions. CTCI actively collaborates with its partners and suppliers to create a green supply chain and aid the green transformation of the entire industry. For example, CTCI set a precedent in Taiwan's engineering service industry in 2024 by aligning its near-term and long-term carbon reduction targets and pathways to the Science Based Targets initiative and passed official review. CTCI has set its target to reduce 45% in Scope 1 and Scope 2 carbon emissions by 2030. Additionally, CTCI's Supplier Alliance for Net Zero Emissions has launched various guidance and incentive measures to encourage Scope 3 supply chain firms—a source of CTCI's carbon emissions that is harder to tackle—to formulate their carbon reduction targets by 2028. In terms of biodiversity, CTCI carries out biodiversity hotspot analysis and remains committed to zero deforestation wherever it implements a project, ensuring conservation of vital species. In alignment with global trends, CTCI has signed the Business for Nature Call to Action, become one of the Early Adopters of the Taskforce on Nature-related Financial Disclosures, and set climate and nature-related targets for risk management and action. With concrete actions in multiple aspects, CTCI demonstrates its determination to protect biodiversity. With regard to the social aspect, CTCI is committed to social care, and spares no effort in promoting talent nurturing and sustainability education. The Group aligns its practices to the UN Sustainable Development Goals, and brings about positive change by working with communities through its charitable arm, CTCI Education Foundation. On the global stage, CTCI Education Foundation is proud to become the 11th Taiwanese NGO admitted to the UN Framework Convention on Climate Change, and continues to participate in the UN Climate Change Conferences, showing the world Taiwan's sustainability achievements. CTCI will continue to firmly uphold its brand ethos as the most reliable engineering services provider, remain committed to be a Guardian of Sustainable Earth, and extend its sustainable engineering influence to make the world a better place. About CTCI CTCI (TWSE: 9933, TPEx: 5209, TPEx: 6803) is a global engineering services provider that offers a comprehensive range of services, products, and solutions. Since its founding in 1979, CTCI has strived to deliver the world's most reliable engineering, procurement, construction, commissioning, operation & maintenance, and project management services. Headquartered in Taipei, Taiwan, CTCI serves the environmental, refinery, petrochemicals, power, transportation, industrial, advanced technology facilities, and LNG receiving terminals markets. The company has about 8,000 employees in around 50 operation bases spanning across more than 10 countries. CTCI aims to become a Guardian of Sustainable Earth by contributing to global sustainability through green engineering, and is committed to wielding its influence in the industry to create a low-carbon supply chain. It continues to engage its partners worldwide to deliver responsible business operations, jointly contributing to the planet's sustainable development. The company is a member of the Dow Jones Sustainability™ Emerging Markets Index.
